List of Opana Er drug patents

Opana Er is owned by Endo Pharms.

Opana Er contains Oxymorphone Hydrochloride.

Opana Er has a total of 11 drug patents out of which 0 drug patents have expired.

Opana Er was authorised for market use on 22 June, 2006.

Opana Er is available in tablet, extended release;oral dosage forms.

Opana Er can be used as relief of moderate to severe pain, dose modification for renal impairment.

The generics of Opana Er are possible to be released after 22 November, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7851482 ENDO PHARMS Method for making analgesics
Jul, 2029

(6 years from now)

US8871779 ENDO PHARMS Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds
Nov, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8329216 ENDO PHARMS Oxymorphone controlled release formulations
Feb, 2023

(4 days from now)

US8309112 ENDO PHARMS Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same
Feb, 2023

(4 days from now)

US8309122 ENDO PHARMS Oxymorphone controlled release formulations
Feb, 2023

(4 days from now)

US7276250 ENDO PHARMS Sustained release formulations of oxymorphone
Feb, 2023

(4 days from now)

US8075872 ENDO PHARMS Abuse-proofed dosage form
Nov, 2023

(9 months from now)

US8309060 ENDO PHARMS Abuse-proofed dosage form
Nov, 2023

(9 months from now)

US8114383 ENDO PHARMS Abuse-proofed dosage form
Aug, 2024

(1 year, 6 months from now)

US8192722 ENDO PHARMS Abuse-proof dosage form
Sep, 2025

(2 years from now)

US8808737 ENDO PHARMS Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment
Jun, 2027

(4 years from now)

Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 22 June, 2006

Treatment: Relief of moderate to severe pain; Dose modification for renal impairment

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in